Pharmaceutical Technology
DECEMBER 25, 2023
Opaganib is under clinical development by RedHill Biopharma and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).
JAMA Internal Medicine
DECEMBER 25, 2023
This randomized clinical trial examines whether an intensive food-as-medicine program can improve glycemic control and ,1rengagement with preventive health care compared with usual care among adults with diabetes and food insecurity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 25, 2023
Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Oligodendroglioma.
Drug Patent Watch
DECEMBER 25, 2023
COREG CR (carvedilol phosphate) Woodward Patent: 7,268,156 Expiration: Dec 27, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com… The post Drug Patent Expirations for the Week of December 24, 2023 appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Technology
DECEMBER 25, 2023
Efineptakin alfa is under clinical development by NeoImmuneTech and currently in Phase II for Solid Tumor.
Pharmaceutical Commerce
DECEMBER 25, 2023
This year’s PC Podcast episodes ranged in topic, from DSCSA compliance to pharmacovigilance.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Drug Patent Watch
DECEMBER 25, 2023
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Finland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Finland? appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Technology
DECEMBER 25, 2023
HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Ovarian Cancer.
Pharmaceutical Technology
DECEMBER 25, 2023
Cabometyx is under clinical development by Exelixis and currently in Phase II for Gastric Cancer.
Pharmaceutical Technology
DECEMBER 25, 2023
ZB-131 is under clinical development by ZielBio and currently in Phase II for Gallbladder Cancer.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
DECEMBER 25, 2023
ION-537 is under clinical development by Ionis Pharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Pharmaceutical Technology
DECEMBER 25, 2023
Cusatuzumab is under clinical development by OncoVerity and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Pharmaceutical Technology
DECEMBER 25, 2023
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Pharmaceutical Technology
DECEMBER 25, 2023
Magrolimab is under clinical development by Gilead Sciences and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
DECEMBER 25, 2023
Sym-023 is under clinical development by Les Laboratoires Servier and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC).
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Central Nervous System (CNS) Tumor.
Pharmaceutical Technology
DECEMBER 25, 2023
Y-101D is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).
Pharmaceutical Technology
DECEMBER 25, 2023
Dabrafenib mesylate is under clinical development by Novartis and currently in Phase II for Gastrointestinal Stromal Tumor (GIST).
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Metastatic Colorectal Cancer.
Pharmaceutical Technology
DECEMBER 25, 2023
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Biliary Tract Cancer.
Pharmaceutical Technology
DECEMBER 25, 2023
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Atopic Keratoconjunctivitis.
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
DECEMBER 25, 2023
Capivasertib is under clinical development by AstraZeneca and currently in Phase III for Triple-Negative Breast Cancer (TNBC).
Pharmaceutical Technology
DECEMBER 25, 2023
Taladegib is under clinical development by Endeavor BioMedicines and currently in Phase II for Idiopathic Pulmonary Fibrosis.
Pharmaceutical Technology
DECEMBER 25, 2023
ADCT-901 is under clinical development by ADC Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC).
Pharmaceutical Technology
DECEMBER 25, 2023
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase III for Diffuse Large B-Cell Lymphoma.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
DECEMBER 25, 2023
ABSK-021 is under clinical development by Abbisko Therapeutics and currently in Phase I for Tenosynovial Giant Cell Tumor.
Pharmaceutical Technology
DECEMBER 25, 2023
XB-002 is under clinical development by Exelixis and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC).
Pharmaceutical Technology
DECEMBER 25, 2023
Y-101D is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Metastatic Colorectal Cancer.
Pharmaceutical Technology
DECEMBER 25, 2023
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Myelodysplastic Syndrome.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
130 
Let's personalize your content